









Markets
/
Stocks
/
nasdaq-prax
/

Praxis Precision Medicines Inc

PRAX

319.570USD

+13.950+4.56%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

6.76BMarket Cap

LossP/E TTM



Praxis Precision Medicines Inc

319.570

+13.950+4.56%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Praxis Precision Medicines Inc

Currency: USD Updated: 2026-02-06

Key Insights

Praxis Precision Medicines Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 53 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 570.38.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Praxis Precision Medicines Inc's Score

Industry at a Glance

Industry Ranking

53 / 392

Overall Ranking

163 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Praxis Precision Medicines Inc Highlights

StrengthsRisks

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.

Growing

The company is in a growing phase, with the latest annual income totaling USD 8.55M.

Undervalued

The company’s latest PE is -24.65, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 25.03M shares, decreasing 20.98% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 11.94K shares of this stock.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

570.375

Target Price

+86.63%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Praxis Precision Medicines Inc is 6.42, ranking 257 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 42.43%.

Score

Industry at a Glance

Previous score

6.42

Change



Financials

6.95

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.21

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.17

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Praxis Precision Medicines Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Praxis Precision Medicines Inc is 5.94, ranking 353 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -24.65, which is -99.38% below the recent high of -0.15 and -1.41% above the recent low of -25.00.

Score

Industry at a Glance

Previous score

5.94

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 53/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Praxis Precision Medicines Inc is 8.27, ranking 144 out of 392 in the Biotechnology & Medical Research industry. The average price target is 340.00, with a high of 760.00 and a low of 65.00.

Score

Industry at a Glance

Previous score

8.27

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

570.375

Target Price

+86.63%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Praxis Precision Medicines Inc

PRAX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Praxis Precision Medicines Inc is 9.66, ranking 3 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 342.01 and the support level at 282.03, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.24

Change

0.42

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-4.163

Neutral

RSI(14)

60.398

Neutral

STOCH(KDJ)(9,3,3)

66.294

Buy

ATR(14)

18.328

Low Volatility

CCI(14)

89.450

Neutral

Williams %R

18.975

Overbought

TRIX(12,20)

0.485

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

309.632

Buy

MA10

309.515

Buy

MA20

305.319

Buy

MA50

275.371

Buy

MA100

199.744

Buy

MA200

122.148

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Praxis Precision Medicines Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 91.34%, representing a quarter-over-quarter decrease of 10.87%. The largest institutional shareholder is Steven Cohen, holding a total of 1.50M shares, representing 5.46% of shares outstanding, with 229.97% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

2.76M

+9.10%

Perceptive Advisors LLC

1.56M

+14.83%

Point72 Asset Management, L.P.

Star Investors

1.50M

+56.80%

The Vanguard Group, Inc.

Star Investors

1.26M

+4.11%

BlackRock Institutional Trust Company, N.A.

1.42M

+3.38%

Adage Capital Management, L.P.

1.31M

-45.02%

Cormorant Asset Management, LP

1.00M

-38.46%

T. Rowe Price Associates, Inc.

Star Investors

974.61K

-32.57%

State Street Investment Management (US)

907.11K

+29.94%

Soleus Capital Management, L.P.

859.17K

-11.13%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Praxis Precision Medicines Inc is 2.04, ranking 258 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.91. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.